BENLYSTA IN MY PRACTICE

Dr. Alvin Wells, Rheumatologist

Paid consultant to GSK at the time of filming.

  • TRANSCRIPT

    DR WELLS: Hi, I’m Doctor Alvin Wells, a board-certified rheumatologist practicing in Franklin, Wisconsin.

    ON-SCREEN TEXT: Dr. Alvin Wells Rheumatologist
    Paid consultant to GSK at the time of filming.

    ON-SCREEN TEXT: “Let’s talk BENLYSTA”

    DR WELLS: I have a busy rheumatology practice, I see over 300 patients a month, and some of those patients have lupus and when they come into my practice, they have significant disease activity. And what does that look like? Most rheumatologists who see lupus will know, they have the mucocutaneous symptoms, the tender and swollen joints, they have the rash, they have the ulcers.

    ON-SCREEN TEXT: 
    • Mucocutaneous symptoms
    • Tender and swollen joints
    • Rash
    • Ulcers

    DR WELLS: 
    And when I think about the patients I have started BENLYSTA on, over the last several years, it has been the whole gamut of patients. I have an 18-year-old lady who just finished high school and going off to college, I have a young mother who has several kids, but I also have older patients in their 40s and 50s. And all of those patients despite their background therapy, what I call standard of care, they still have disease activity and that’s why I have been using BENLYSTA in those patients.

    ON-SCREEN TEXT: 
    “That’s why I have been using BENLYSTA”

    DR WELLS: As an immunologist, I know how the drug works, the mechanism of action, ...

    ON-SCREEN TEXT:
    “I know how the drugs works”

     

    DR WELLS: 
    ...I know the impact that it has on the signs and symptoms and that’s when I am really demanding, when I think about treating patients who have lupus.

    ON-SCREEN TEXT: “I know the impact”

    DR WELLS: So, as I follow these patients over years, you know, month to month, I am looking for improvement in all of the disease activities. The addition of BENLYSTA has made a very very useful component in my armamentarium in treating patients with lupus disease activity.

    ON-SCREEN TEXT: “BENLYSTA: a very useful component in my armamentarium”

    DR WELLS: Thank you for watching. Visit the BENLYSTA website for more information.

    ON-SCREEN TEXT: Visit the website

    ON-SCREEN TEXT: BENLYSTA is indicated for patients aged ≥5 with active, autoantibody-positive systemic lupus erythematosus (SLE) receiving standard therapy and patients aged ≥18 with active lupus nephritis receiving standard therapy. BENLYSTA is not recommended in patients with severe active central nervous system lupus or in combination with other biologics.

    IMPORTANT SAFETY INFORMATION

    CONTRAINDICATION

    Previous anaphylaxis with BENLYSTA.

    Serious Infections: Serious and sometimes fatal infections have been reported and occurred more frequently with BENLYSTA. Use caution in patients with severe or chronic infections, and consider interrupting therapy in patients with a new infection.

    Progressive Multifocal Leukoencephalopathy (PML): Cases of JC virus-associated PML resulting in neurological deficits, including fatal cases, have been reported. If PML is confirmed, consider stopping immunosuppressant therapy, including BENLYSTA.

    Please see additional Important Safety Information and full Prescribing Information, including Medication Guide, on the BENLYSTAHCP.com website.

    ON-SCREEN TEXT:
    BENLYSTA
    (belimumab)
    Intravenous Use 120 mg/vial
    Subcutaneous Use 200 mg/mL

    GSK Logo

    Trademarks are owned by or licensed to the GSK group of companies. |
    ©2022 GSK or licensor. BELVID220006 March 2022. Produced in USA.

You may also like

WHY BENLYSTA?

Dr. Alvin Wells, Rheumatologist

BENLYSTA PATIENT CASE

Dr. Alvin Wells, Rheumatologist

JOIN US FOR
A LIVE WEBINAR

Paid consultants to GSK at the time of filming.